Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities

Sibel Ülker, Pascal P. McKeown, Ulvi Bayraktutan

Abstract—Antioxidant vitamins C and E have protective properties in genetic hypertension associated with enhanced oxidative stress. This study investigated whether vitamins C and/or E modulate vascular function by regulating enzymatic activities of endothelial nitric oxide synthase (eNOS) and NAD(P)H oxidase using thoracic aortas of 20- to 22-week-old male spontaneously hypertensive rats (SHR) and their matched normotensive counterparts, Wistar-Kyoto rats (WKY). SHR aortas had impaired relaxant responses to acetylcholine but not to sodium nitroprusside, despite an ≈2-fold increase in eNOS activity and NO release. The levels of superoxide anion (O$_2^{-}$), a potent NO scavenger, and NAD(P)H oxidase activity were also 2-fold higher in SHR aortas. Mechanical but not pharmacological inactivation of endothelium (by rubbing and 100 μmol/L L-NAME, respectively) significantly abrogated O$_2^{-}$ in both strains. Treatments of SHR aortas with NAD(P)H oxidase inhibitors, namely diphenyleneiodinium and apocynin, significantly diminished O$_2^{-}$ production. The incubation of SHR aortas with different concentrations of vitamin C (10 to 100 μmol/L) and specifically with high concentrations of vitamin E (100 μmol/L) improved endothelial function, reduced superoxide production as well as NAD(P)H oxidase activity, and increased eNOS activity and NO generation in SHR aortas to the levels observed in vitamin C- and E-treated WKY aortas. Our results reveal endothelial NAD(P)H oxidase as the major source of vascular O$_2^{-}$ in SHR and also show that vitamins C and E are critical in normalizing genetic endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. (Hypertension. 2003;41:1638–1644.)

Key Words: nitric oxide ■ endothelium ■ enzymes ■ antioxidants ■ hypertension, experimental ■ vitamins

The endothelium plays pivotal roles in the maintenance of vascular tone and blood pressure by regulating the release of several vasoactive substances, including nitric oxide (NO). However, its characteristics change in pathological conditions leading to a phenomenon called “endothelial dysfunction,” which is characterized by impaired endothelium-dependent relaxation. Endothelial dysfunction has been reported in conduit and resistance arteries of both essential hypertensive patients and various animal models of essential hypertension.

Current data as to the pathogenesis of endothelial dysfunction are extremely diverse. Diminished production of NO caused by either inefficient utilization of substrate L-arginine or impaired expression/activity of endothelial NO synthase (eNOS) and impaired endothelium-derived hyperpolarizing factor-mediated hyperpolarization of resistance vessels have been implicated in this process. However, a single unifying mechanism has yet to emerge.

NO, generated within vascular endothelium by eNOS, is considered the most important endothelium-derived vasodilator in conduit arteries. Although eNOS is constitutively expressed, many pathophysiological stimuli may regulate its expression. Indeed, sex hormones elicit an increase in eNOS gene expression, whereas hypoxia downregulates its expression. The current data on the molecular regulation of eNOS in the cardiovascular system in essential hypertension are rather conflicting. Increased, decreased and unaltered levels of eNOS expression have thus far been reported in SHR.

In recent years, exaggerated vascular production of reactive oxygen species (ROS), in particular O$_2^{-}$ by NAD(P)H oxidase and/or uncoupled state of eNOS as a result of its activation at suboptimal concentrations of its cofactor tetrahydrobiopterin (H$_4$B) or diminished metabolism of ROS by antioxidant enzymes or impaired regeneration of reduced antioxidants, has been associated with the pathogenesis of this phenomenon in hypercholesterolemia and stroke prone SHR (SHRSP).

ROS modulate vascular function by scavenging NO and producing peroxynitrite (OONO$^-$) in the process. OONO$^-$, another ROS, oxidizes proteins and elicits both breakage in DNA structure and shortage of intracellular antioxidants such as glutathione and cysteine. ROS are also involved in the oxidative modification of LDL.

Several recent studies have shown the beneficial effects of treatments with antioxidants such as allopurinol and hydrosoluble coenzyme Q10 in patients with diabetes mellitus and insulin-resistant hypertension, respectively. An accumulating body of evidence has also demonstrated that anti-

Received November 12, 2002; first decision December 6, 2002; revision accepted January 9, 2003.

From the Department of Medicine, Institute of Clinical Science Block B, Queen’s University Belfast, Belfast, United Kingdom.

Correspondence to Dr Ulvi Bayraktutan, Department of Medicine, Institute of Clinical Science Block B, Queen’s University of Belfast, Grosvenor Road, Belfast BT12 6BJ, UK. E-mail u.bayraktutan@qub.ac.uk

© 2003 American Heart Association, Inc.

Hypertension is available at http://www.hypertensionaha.org

DOI: 10.1161/01.HYP.0000057421.28533.37
oxidant vitamins C and E are also implicated in the improvement of endothelial function in human subjects and in animal models of human diseases including hypertension.18–20 Indeed, vitamin C alone or in combination with vitamin E has been shown to enhance NO generation and reduce blood pressure in hypertensive animals.21 Moreover, dietary supplementation of vitamin E has been shown to enhance total antioxidant status and reduce blood pressure in SHR.18,22 Although both antioxidant vitamins are known to stimulate NO generation in endothelial cells and have ROS-scavenging effects, the underlying mechanisms of action are unknown.22,23

The purpose of the present study was therefore to investigate whether vitamins C and E improve endothelial function in SHR aortas by alteration of the redox state through regulation of the enzymatic activities of eNOS and NAD(P)H oxidase and therefore release of NO and O$_2^-$, respectively.

**Methods**

**Animals and Thoracic Aorta Preparation**

The studies were performed with thoracic aortas obtained from 20- to 22-week-old male SHR and their age- and gender-matched normotensive counterparts, Wistar-Kyoto rats (WKY). Thoracic aortas were removed from anticoagulated rats (100 U heparin IV) under deep sodium pentobarbitol anesthesia (100 mg/kg body IP) and constantly gassed with carbogen (95% O$_2$/5% CO$_2$) until use. Aortic homogenates were prepared on ice in lysis buffer containing 0.2% Triton X-100, 150 mmol/L NaCl, 20 mmol/L HEPES, pH 7.4, and 1 mmol/L phenylmethylsulfonyl fluoride (PMSF). Samples were incubated at 37°C for 30 minutes in the presence of calmodulin (30 nmol/L), NADPH (1 mmol/L), H$_2$B (5 mmol/L), Ca$^{2+}$ (2 mmol/L), L-valine (50 mmol/L), and a mixture of unlabeled (0 to 5 mmol/L) and L-[14C]-arginine (10 mmol/L) (Amersham Pharmacia). To assess the contribution of iNOS (calcium-independent isoform) to overall NOS activity, Ca$^{2+}$ was replaced with EGTA (1 mmol/L). Reactions were terminated by the addition of 1 mL HEPES (20 mmol/L, pH 5.5) containing EDTA (1 mmol/L) and EGTA (1 mmol/L). Newly formed L-[14C]-arginine, neutral at pH 5.5, was separated from the incubation mixture by cation exchange resin (Dowex AG 50 W-X8, Bio-Rad) and quantified by a liquid scintillation counter. Results were expressed as picomoles of L-citrulline per milligram of protein per minute.

**Nitrite Detection**

Nitrite levels were measured in aortic homogenates by Griess reaction as index of NO generation after conversion of nitrate to nitrite by nitrate dehydrogenase.24 An aliquot of the supernatant was mixed with an equal volume of Griess reagent (sulfanilamide, 1% wt/vol; naphthylethylenediamine dihydrochloride, 0.1% wt/vol; and orthophosphoric acid, 2.5% vol/vol) and incubated at room temperature for 10 minutes. The absorbance of the samples was determined at 540 nm wavelength and compared with those of known concentrations of sodium nitrite. The amount of nitrite formed was normalized to the protein content of the respective aorta.

**NADH/NADPH Oxidase Activity**

Aortic homogenates were prepared on ice in lysis buffer containing 1 mmol/L EGTA, 20 mmol/L monobasic potassium phosphate (pH 7.0), 0.5 mmol/L leupeptin, 0.7 mmol/L pepstatin, 10 mmol/L apotinin, and 0.3 mmol/L PMSF. Oxidase activity was measured by lucigenin-enhanced chemiluminescent detection of superoxide in a luminometer. The reaction was initiated by the addition of 200 μg of total protein to reaction buffer containing 1 mmol/L EGTA, 150 mmol/L sucrose, 5 mmol/L lucigenin, and 1 mmol/L NADH or NADPH. Luminescence was calculated as the rate of counts per mg protein after deduction of the counts obtained from a buffer blank.

**Detection of Vascular O$_2^-$ by Lucigenin-Enhanced Chemiluminescence**

Aortic segments were prepared as described above. Approximately 5-mm-long rings were transferred into tubes containing HEPES buffer and incubated at 37°C for 30 minutes before addition of 5 μmol/L of lucigenin. Luminescence was measured as above.

**Statistical Analysis**

Data are expressed as mean±SEM. Numbers (n) indicated throughout the article denote the number of animals used in vascular reactivity studies or enzymatic assays. Dose-response curves were fitted by nonlinear regression with simplex algorithm. Relaxant responses were given as the percentages of PE precontraction. Comparisons of dose-response curves were evaluated by 2-way ANOVA for repeated measures. Probability values <0.05 were considered to be statistically significant.

**Results**

**General Data**

The systolic blood pressure and the heart weight/body weight ratio were significantly higher in SHR compared with WKY.
However, there was no significant difference in body weight or basal heart rate between the 2 groups (Table 1).

Levels of eNOS and NAD(P)H Oxidase Activity and NO and $O_2^-$ in WKY and SHR Aorta Before and After Treatments With Vitamins C and E

The activities of eNOS and NAD(P)H oxidase were found to be significantly higher in SHR aortic homogenates before treatments with either vitamin. However, the treatments with vitamin C (any dose used between 10 and 100 µmol/L) and higher concentrations of vitamin E (100 µmol/L) decreased NAD(P)H oxidase activity and $O_2^-$ production but increased eNOS activity and NO generation to the levels observed in vitamin C- and E-treated WKY aortas (Table 2).

Enzymatic and Cellular Sources of $O_2^-$ in WKY and SHR Aorta

Endothelial NOS activity was abrogated in SHR and WKY aortas through mechanical and pharmacological removal of the endothelium by rubbing and incubation with $N_n$-nitro-$L$-arginine methyl ester (L-NAME, 100 µmol/L) for 1 hour before quantification of $O_2^-$ levels. Although the mechanical removal of endothelium significantly reduced the basal level of $O_2^-$ in both strains, the decrease was not significant in response to treatments with L-NAME in either strain (Table 3). In contrast, the treatment of SHR aortas with 2 different inhibitors of NAD(P)H oxidase, namely apocynin and diphenyleneiodonium (DPI, 10 and 100 µmol/L), elicited a significant reduction in $O_2^-$ production in a dose-dependent manner, indicating this enzyme as the main source of vascular $O_2^-$ (Table 3).

Vasodilator Responses in Thoracic Aorta

In PE-precontracted aortic rings, although ACh produced a concentration-dependent relaxation in WKY, it generated contractile responses in SHR at higher doses, indicating a defect in vascular endothelium (Figure 1A). There was no difference in the relaxant responses of SHR and WKY rings to incremental concentrations of SNP, an endothelium-independent relaxant (Figure 1B).

Effects of Vitamins C and E on Vasodilation

To determine whether antioxidant vitamins potentiate the vasodilatory effects of ACh in SHR and WKY aortas, the rings from both species were treated with 4 different concentrations of these vitamins (10, 25, 50, and 100 µmol/L) for 20 minutes before investigation of relaxant responses. All concentrations of vitamin C elicited significant relaxation in SHR rings compared with WKY (Figure 2). In contrast, only the highest concentration of vitamin E (100 µmol/L) improved endothelial function in SHR suggesting a dose-dependency for the beneficial effects of vitamin E (Figure 3).

Discussion

The major conclusions to be drawn from this study are that the antioxidant properties of vitamins C and E are associated with decreased activation of NAD(P)H oxidase and hence generation of $O_2^-$ and enhanced activation of eNOS and therefore generation of NO. These findings provide crucial

### Table 1. Biological Variables in 20–22-Week-Old SHR Compared With WKY

<table>
<thead>
<tr>
<th>Biological Parameters</th>
<th>SHR</th>
<th>WKY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart weight/body weight, mg/g</td>
<td>3.63 ± 0.21*</td>
<td>3.10 ± 0.18</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>188 ± 13*</td>
<td>140 ± 11</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>398 ± 39</td>
<td>387 ± 26</td>
</tr>
<tr>
<td>Basal heart rate, bpm</td>
<td>257 ± 19</td>
<td>244 ± 28</td>
</tr>
</tbody>
</table>

Data are mean ± SEM (n = 30).

*P < 0.05.

### Table 2. Levels of eNOS and NAD(P)H Oxidase Activity and Nitrite and $O_2^-$ in WKY and SHR Aortas Before and After Treatments With 100 µmol/L Vitamin C and E

<table>
<thead>
<tr>
<th>Group</th>
<th>eNOS Activity (pmol L-citrulline/min/mg protein)</th>
<th>NADPH Oxidase (counts/min/mg protein)</th>
<th>Nitrite Levels (nmol/mg protein)</th>
<th>NADPH Oxidase (counts/min/mg protein)</th>
<th>$O_2^-$ Levels (counts/min/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td>0.38 ± 0.08†</td>
<td>4350 ± 280†</td>
<td>8.85 ± 0.60†</td>
<td>120 ± 19†</td>
<td>320 ± 18†</td>
</tr>
<tr>
<td>WKY</td>
<td>0.15 ± 0.04</td>
<td>2100 ± 220</td>
<td>5.70 ± 0.80</td>
<td>1520 ± 178</td>
<td>180 ± 25†</td>
</tr>
<tr>
<td>SHR + vit C</td>
<td>0.82 ± 0.06</td>
<td>1520 ± 178</td>
<td>13.90 ± 1.30</td>
<td>152 ± 18</td>
<td>169 ± 30†</td>
</tr>
<tr>
<td>WKY + vit C</td>
<td>0.75 ± 0.08</td>
<td>1740 ± 135</td>
<td>13.30 ± 1.10</td>
<td>183 ± 16</td>
<td>161 ± 19†</td>
</tr>
<tr>
<td>SHR + vit E</td>
<td>0.73 ± 0.09</td>
<td>1690 ± 120</td>
<td>11.20 ± 0.65</td>
<td>179 ± 25</td>
<td>187 ± 22†</td>
</tr>
<tr>
<td>WKY + vit E</td>
<td>0.71 ± 0.05</td>
<td>1785 ± 190</td>
<td>11.75 ± 0.95</td>
<td>195 ± 34</td>
<td>163 ± 17†</td>
</tr>
</tbody>
</table>

Data are mean ± SEM (n = 6 for each group of rats).

*P < 0.05, difference within each group. Vitamin C or E-treated vs untreated. †P < 0.05, difference between 2 groups, SHR vs WKY.
evidence as to how antioxidant vitamins C and E may improve vascular endothelial function in addition to their well-established free radical-scavenging effects.

Vitamins C and E, along with the other low-molecular-weight antioxidants such as urate and thiols, constitute the first line of defense against oxidative stress in the extracellular environment. These antioxidants prevent oxidation of proteins and lipids by scavenging free oxygen radicals at the expense of being consumed in the process. It is therefore plausible to suggest that the levels of these antioxidants may reflect the severity of resistance to oxidative stress. A close association between the alleviation of hypertension and treatments with these vitamins has been shown in experimental models of hypertension, including SHR and salt-loaded SHRSP. A consistent beneficial effect of vitamin C has been reported in human subjects in that acute intra-arterial administration of vitamin C to patients with diabetes mellitus improves endothelium-dependent vascular relaxation. Similarly, physiological and supraphysiological concentrations of vitamin C have been shown to reverse endothelial dysfunction in conduit arteries of patients with congestive heart failure and hypertension, respectively. However, clinical data pertaining to beneficial effects of vitamin E have been mixed. A randomized study, the Cambridge Heart Antioxidant Study (CHAOS), revealed a marked reduction in nonfatal myocardial infarction in patients randomly assigned to treatment with 400 to 800 IU of vitamin E per day compared with patients receiving placebo. Nevertheless, several subsequent studies including the Heart Outcomes Prevention Evaluation (HOPE) study have failed to confirm these findings.

In the present study, vitamin C (10 to 100 μmol/L) and high concentrations of vitamin E (100 μmol/L) improved endothelial function in the thoracic aortas of 20- to 22-week-old male SHR to the levels that were observed in matching normotensive WKY. Putative mechanisms whereby antioxidant vitamins improve endothelial function may be due to (1) their direct free radical-scavenging ability; (2) their ability to regulate NO synthases that generate NO; (3) their ability to regulate enzymes such as NAD(P)H oxidase that generate free radicals; or (4) their ability to regulate antioxidant enzymes, including superoxide dismutases (SODs), which metabolize free radicals. The free radical-scavenging effects of antioxidant vitamins are well documented. Similarly, physiological and supraphysiological concentrations of vitamin C have been shown to reverse endothelial dysfunction in conduit arteries of patients with congestive heart failure and hypertension, respectively. However, clinical data pertaining to beneficial effects of vitamin E have been mixed. A randomized study, the Cambridge Heart Antioxidant Study (CHAOS), revealed a marked reduction in nonfatal myocardial infarction in patients randomly assigned to treatment with 400 to 800 IU of vitamin E per day compared with patients receiving placebo. Nevertheless, several sub-
vascular endothelium. On the other hand, SNP, an endothelium-dependent vasorelaxant, produced the same degree of endothelium-independent relaxant, produced the same degree of endothelium-independent vasorelaxant in the thoracic aortas of both strain. The mechanisms by which vitamins C and E may modulate NAD(P)H oxidase or eNOS activities are unclear; it has been suggested that vitamins may be involved in both the transcription and posttranslational modification of NAD(P)H oxidase and perhaps eNOS. Vitamin E, a lipophilic antioxidant, may modulate the interactions between cytochrome b558, the membrane-bound part of NAD(P)H oxidase enzyme that is required for enzyme activity and stability as a whole, and the cytosolic components of this enzyme system that translocate to the plasma membrane on activation. Moreover, vitamin E is taken up by LDL particles and therefore improves endothelial function by reducing the sensitivity of LDL to in vitro oxidation in healthy subjects as well as type 2 diabetics. However, other studies have shown that in vitro or in vivo enrichment of LDL with α-tocopherol accelerates rather than inhibits LDL oxidation if there is a shortage of other antioxidants including vitamin C in the environment. This suggests that vitamin C may mediate some of its functions through vitamin E. Vitamin C, in addition to its direct ROS-scavenging effects, may also have other beneficial effects as the result of its ability to increase the availability of the eNOS cofactor Hb, thereby enhancing eNOS activity.

Data from this study confirm the involvement of oxidative stress in the pathogenesis of genetic endothelial dysfunction and indicate a requirement for a relatively higher dose of vitamin E compared with vitamin C to improve vascular relaxation. It also sheds some light as to why discrepant results have been reported in response to treatments with vitamin E.

We have demonstrated in the present study that treatment with vitamins C and high doses of vitamin E reverse impaired endothelium-dependent vascular relaxation in a genetic model of eNOS. However, treatments of SHR aortas with different concentrations of vitamin C (10 to 100 μmol/L) and higher concentrations of vitamin E (100 μmol/L) diminished generation of O₂⁻ and activation of NAD(P)H oxidase in SHR aortic homogenates, suggesting a vascular protective role for both of these vitamins provided that an adequate dose is chosen, particularly in case of vitamin E. To determine the contribution of eNOS to vascular O₂⁻ production, we removed endothelium from vessels by rubbing or by incubating with an eNOS inhibitor, L-NAME. The mechanical removal of endothelium significantly but not fully reduced the basal level of O₂⁻ in both SHR and WKY aortas, thereby suggesting that vascular smooth muscle cells and adventitial fibroblasts may be alternative sources of O₂⁻ generation. However, the decrease in the O₂⁻ was not significant in response to treatments with L-NAME in both strains, indicating NAD(P)H oxidase as the main source of O₂⁻ in SHR at 20 to 22 weeks age, the well-established hypertensive stage. To further verify this hypothesis, we treated SHR aortas with specific inhibitors of NAD(P)H oxidase, for example, apocynin and DPI, and showed that both inhibitors reduced O₂⁻ production significantly in a dose-dependent manner (Table 3).

Although this study did not investigate either vascular SOD activity or total antioxidant status, a previous study showed significant elevations in both of these parameters in another model of genetic hypertension, salt-loaded SHRSP. The mechanisms by which vitamins C and E may modulate NAD(P)H oxidase or eNOS activities are unclear; it has been suggested that vitamins may be involved in both the transcription and posttranslational modification of NAD(P)H oxidase and perhaps eNOS. Vitamin E, a lipophilic antioxidant, may modulate the interactions between cytochrome b558, the membrane-bound part of NAD(P)H oxidase enzyme that is required for enzyme activity and stability as a whole, and the cytosolic components of this enzyme system that translocate to the plasma membrane on activation. Moreover, vitamin E is taken up by LDL particles and therefore improves endothelial function by reducing the sensitivity of LDL to in vitro oxidation in healthy subjects as well as type 2 diabetics. However, other studies have shown that in vitro or in vivo enrichment of LDL with α-tocopherol accelerates rather than inhibits LDL oxidation if there is a shortage of other antioxidants including vitamin C in the environment. This suggests that vitamin C may mediate some of its functions through vitamin E. Vitamin C, in addition to its direct ROS-scavenging effects, may also have other beneficial effects as the result of its ability to increase the availability of the eNOS cofactor Hb, thereby enhancing eNOS activity.

Data from this study confirm the involvement of oxidative stress in the pathogenesis of genetic endothelial dysfunction and indicate a requirement for a relatively higher dose of vitamin E compared with vitamin C to improve vascular relaxation. It also sheds some light as to why discrepant results have been reported in response to treatments with vitamin E.

We have demonstrated in the present study that treatment with vitamins C and high doses of vitamin E reverse impaired endothelium-dependent vascular relaxation in a genetic model of eNOS. However, treatments of SHR aortas with different concentrations of vitamin C (10 to 100 μmol/L) and higher concentrations of vitamin E (100 μmol/L) diminished generation of O₂⁻ and activation of NAD(P)H oxidase in SHR aortic homogenates, suggesting a vascular protective role for both of these vitamins provided that an adequate dose is chosen, particularly in case of vitamin E. To determine the contribution of eNOS to vascular O₂⁻ production, we removed endothelium from vessels by rubbing or by incubating with an eNOS inhibitor, L-NAME. The mechanical removal of endothelium significantly but not fully reduced the basal level of O₂⁻ in both SHR and WKY aortas, thereby suggesting that vascular smooth muscle cells and adventitial fibroblasts may be alternative sources of O₂⁻ generation. However, the decrease in the O₂⁻ was not significant in response to treatments with L-NAME in both strains, indicating NAD(P)H oxidase as the main source of O₂⁻ in SHR at 20 to 22 weeks age, the well-established hypertensive stage. To further verify this hypothesis, we treated SHR aortas with specific inhibitors of NAD(P)H oxidase, for example, apocynin and DPI, and showed that both inhibitors reduced O₂⁻ production significantly in a dose-dependent manner (Table 3).

Although this study did not investigate either vascular SOD activity or total antioxidant status, a previous study showed significant elevations in both of these parameters in another model of genetic hypertension, salt-loaded SHRSP. The mechanisms by which vitamins C and E may modulate NAD(P)H oxidase or eNOS activities are unclear; it has been suggested that vitamins may be involved in both the transcription and posttranslational modification of NAD(P)H oxidase and perhaps eNOS. Vitamin E, a lipophilic antioxidant, may modulate the interactions between cytochrome b558, the membrane-bound part of NAD(P)H oxidase enzyme that is required for enzyme activity and stability as a whole, and the cytosolic components of this enzyme system that translocate to the plasma membrane on activation. Moreover, vitamin E is taken up by LDL particles and therefore improves endothelial function by reducing the sensitivity of LDL to in vitro oxidation in healthy subjects as well as type 2 diabetics. However, other studies have shown that in vitro or in vivo enrichment of LDL with α-tocopherol accelerates rather than inhibits LDL oxidation if there is a shortage of other antioxidants including vitamin C in the environment. This suggests that vitamin C may mediate some of its functions through vitamin E. Vitamin C, in addition to its direct ROS-scavenging effects, may also have other beneficial effects as the result of its ability to increase the availability of the eNOS cofactor Hb, thereby enhancing eNOS activity.
model of human essential hypertension. These effects are associated with enhanced generation of NO and activity of eNOS as well as diminished production of O$_2^-$ and activity of NAD(P)H oxidase. These findings provide important evidence for the use of adequate levels of antioxidant vitamins C and E in the treatments of pathologies that are associated with oxidative stress.

Acknowledgments
This work was supported by grants obtained from the Heart Trust Fund (Royal Victoria Hospital, Belfast) and the Royal Society, UK.

References
Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities
Sibel Ülker, Pascal P. McKeown and Ulvi Bayraktutan

Hypertension, published online February 17, 2003;
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2003/02/17/01.HYP.0000057421.28533.37.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/